Richard Murray, Jounce Therapeutics CEO
Jounce nixes Redx offer as I/O biotech instead goes with Concentra Biosciences’ takeover bid
A minority shareholder has won out in the Jounce Therapeutics takeover battle, with the once-ambitious immunotherapy biotech now choosing to be
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
